Cerevia Neurosciences sits in early-stage therapeutic neuromodulation for dementia, combining fMRI-guided targeting, TMS, and adaptive stimulation logic. Its positioning is differentiated by the attempt to bring imaging-informed network modulation into a compact clinical platform for cognitive impairment.